Intranasal Insulin for Weight Management During Smoking Cessation

Completed · Phase 2 · Has a placebo group

Conditions studied: Tobacco Abstinence Syndrome

In brief

This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.

Key facts

Study ID

NCT02028871

Run by

Ajna Hamidovic

People needed

26

Starts

2014-07-01

Expected to finish

2016-05-01

Last updated by the study team

2018-12-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• smokers (>10 cig/day) for the past 1 year
• normosmic olfactory function

You may not qualify if…

• previous/current use of insulin
• current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder
• current pregnancy (or lactation)
• lifetime history of endocrine disease
• excessive alcohol use (>25 standard units of alcohol/week)
• current use of illicit drugs
• current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent
• local infections, inflammation, structural abnormalities, or other nasal pathology
• current use of any medications administered intranasally, including intranasal steroids

Where it is running

• UNM College of Pharmacy — Albuquerque, New Mexico, United States
• UNM College of Pharmacy — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.